CDIO (Cardio Diagnostics Holdings) Net Margin % : -30,380.00% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cardio Diagnostics Holdings's Net Income for the three months ended in Dec. 2024 was $-1.52 Mil. Cardio Diagnostics Holdings's Revenue for the three months ended in Dec. 2024 was $0.01 Mil. Therefore, Cardio Diagnostics Holdings's net margin for the quarter that ended in Dec. 2024 was -30,380.00%.

The historical rank and industry rank for Cardio Diagnostics Holdings's Net Margin % or its related term are showing as below:

CDIO' s Net Margin % Range Over the Past 10 Years
Min: -466100 Med: -55638.24 Max: -23288.89
Current: -23288.89

CDIO's Net Margin % is ranked worse than
94.4% of 1000 companies
in the Biotechnology industry
Industry Median: -126.84 vs CDIO: -23288.89

Cardio Diagnostics Holdings Net Margin % Historical Data

The historical data trend for Cardio Diagnostics Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Net Margin % Chart

Cardio Diagnostics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

-62,000.00

-466,100.00

-49,276.47

-23,951.43

Cardio Diagnostics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial											-27,780.00	-26,025.00	-16,100.00	-20,185.71	-30,380.00

Competitive Comparison of Cardio Diagnostics Holdings's Net Margin %

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Net Margin % falls into.

Save Embed

;

Save Embed

;

Cardio Diagnostics Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cardio Diagnostics Holdings's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-8.383	/	0.035
	=	-23,951.43 %

Cardio Diagnostics Holdings's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-1.519	/	0.005
	=	-30,380.00 %

Cardio Diagnostics Holdings (NAS:CDIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cardio Diagnostics Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West Superior Street, Suite 444, Chicago, IL, USA, 60654

Website

https://www.cardiodiagnosticsinc.com

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Executives

Robert Philibert	director, 10 percent owner, officer: Chief Medical Officer	400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan	officer: Chief Technology Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan	director, 10 percent owner, officer: Chief Executive Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion	director	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman	officer: Chief Financial Officer	37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi	officer: VP of Revenue and Strategy	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim	director	C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc.	10 percent owner	15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater	officer: CEO	223 PALMER STREET, PALMER MA 01069
Allan Liu	director	1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman	director	207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc	10 percent owner	8 THE GREEN, SUITE A, DOVER DE 19901